A new class of MPN Challenge™ projects is on the horizon. Following a rigorous review process, MPN Research Foundation is funding 8 research teams to pursue innovative ideas spanning artificial intelligence, disease biology, and emerging therapeutic strategies. Get an early look at the themes shaping this year's portfolio. 

A 7-minute walk does not sound difficult until it is January in St. Louis. For graduate student Aishwarya Krishnan, that trek through wind, snow, and slush leads to the mouse facility where long experimental days begin and where the next generation of blood cancer research is taking shape.

Myeloproliferative neoplasms (MPNs) are rare blood cancers that often unfold slowly. Some people live with stable disease for many years, while others experience progression to myelofibrosis or acute myeloid leukemia (AML). Understanding why these paths differ is a central challenge in MPN research. 

A new study, Genomic evolution and natural history of myeloproliferative neoplasms on therapy, led by researchers including Dr. Jyoti Nangalia, takes a long view of this question (Leongamornlert et al., 2026). The project tracks how the genetic makeup of MPN patients change over time and across diagnoses.